Background {#Sec1}
==========

Long-term health conditions (LTCs, chronic physical and mental disorders) are by far the largest contributor to health loss in New Zealand (NZ), accounting for 88% of disability-adjusted life years \[[@CR1]\]. The economic cost and burden on the health system is substantial and growing \[[@CR1], [@CR2]\]. Type 2 diabetes mellitus (T2DM) is one of the most common long-term conditions affecting NZ adults, with a prevalence of around 7% based on glycosylated haemoglobin (HbA1c) data from the 2008/09 NZ Adult Nutrition Survey \[[@CR3]\]. Furthermore, the prevalence of T2DM is rapidly increasing in NZ at a rate of 7% per annum \[[@CR2]\]. Māori, Pacific and Indian people have particularly high rates of T2DM, with rates up to three times higher than European New Zealanders \[[@CR2], [@CR3]\]. Diabetes is associated with multiple long-term complications, higher mortality and substantial healthcare costs \[[@CR2], [@CR4]\]. Pre-diabetes is a precursor stage to T2DM with up to 70% eventually progressing on to T2DM; many people with pre-diabetes already have some of the complications of T2DM \[[@CR5]--[@CR8]\]. The estimated prevalence of pre-diabetes in NZ adults is 26% \[[@CR2]\].

Self-management measures, such as a healthy diet, regular exercise and weight management, are key to preventing the progression of pre-diabetes to T2DM, controlling T2DM and reducing complications \[[@CR9]--[@CR13]\]. For example, the Diabetes Prevention Program (DPP) study found that a lifestyle intervention resulted in a 58% reduction in incidence of diabetes among a high-risk population without diabetes, and that even short-term reversion to normal glucose control among those with pre-diabetes substantially reduced the likelihood that the person would progress to T2DM \[[@CR12], [@CR13]\]. Similarly, those with diabetes who undergo lifestyle interventions tend to have better glycaemic control and improved long-term outcomes \[[@CR9]\]. However, many people struggle to initiate and maintain these strategies \[[@CR14], [@CR15]\].

Self-management strategies for T2DM have resulted in improvements in glycaemic control \[[@CR16]--[@CR18]\], weight loss \[[@CR17], [@CR18]\], patient satisfaction with healthcare \[[@CR17]\], self-efficacy \[[@CR19]\] and adherence to medication \[[@CR20]\]. There is less evidence to support the use of self-management programmes in those with pre-diabetes. One study assessed the outcomes of an Internet-based diabetes prevention programme for people with pre-diabetes and found that there were clinically significant reductions in body weight and HbA1c at 2 years after entry into the programme \[[@CR21]\].

The BetaMe Programme is an integrated self-management programme for T2DM and pre-diabetes developed by Melon Health Ltd. \[[@CR22]\] with a strong emphasis on engagement, education and activation of patients with LTCs. Its foundations are based in behavioural-change theory using cognitive behavioural theory, motivational interviewing, goal setting, health tracking, reminders and intrinsic rewards to support and encourage positive behaviour change \[[@CR16], [@CR23], [@CR24]\]. BetaMe was developed in partnership with a multidisciplinary team including primary care practitioners, Māori and Pacific health providers, and psychologists. The programme incorporates access to expert one-on-one coaching, decision support and peer support, all of which are evidence-based approaches to increasing the effectiveness of self-management support (see Table [1](#Tab1){ref-type="table"}).Table 1Components of the BetaMe programme and evidence of their effectivenessStageElementWhat is providedEvidence-based for effective self-managementCore only (weeks 1--16)Health coachesShared goal setting, and personalised programme based on that person's personal goals. Provide regular input, encouragement and support via messaging and fortnightly video or audio meetingsEducational programmes and individual support through personalised coaches has been shown to be effective, with the level of effectiveness dependent on the intensity of the programme \[[@CR50]\]. A number of successful interventions have provided access to an 'expert', such as a personal trainer or dietician, coupled with support from health professionals \[[@CR51], [@CR52]\]Health literacyFortnightly evidence-based resources and behaviour-change tools delivered in consumer-centred formats (bite sized, simple messages, images and video)Mobile phones to send reminders or educational information via text, or within applications, have proven beneficial in the management of chronic conditions such as diabetes \[[@CR53]\] with positive outcomes relating to glycaemic control and patient satisfaction, \[[@CR17]\] self-efficacy \[[@CR19]\] medication adherence \[[@CR20]\] and as a result of weight loss, reduced transition from pre-diabetes to diabetes \[[@CR54]\]Core and maintenance (weeks 1--52)Goal trackingDaily reminders via web-based devices. Daily goal tracking of exercise, happiness, energy levels, food and weekly tracking of weight and waist measureGoal tracking, such as the regular monitoring of weight or laboratory data has been identified as a key component of successful self-management programmes to achieve weight loss \[[@CR55]\], and improved long-term outcomes \[[@CR56]\]Peer supportOnline closed forum, monitored by a registered nursePeer support has been successful in improving glycaemic control \[[@CR57]--[@CR61]\] and has been identified by participants, to be the most useful component of a self-management programme \[[@CR57]\]

BetaMe is delivered using both mobile and web-based platforms in a 12-month programme with four key components: health coaching, provision of evidence-based resources, peer support and goal tracking. Each component has demonstrated benefits for improved outcomes for people with T2DM or pre-diabetes (summarised in Table [1](#Tab1){ref-type="table"}). The first 16 weeks form the core part of the programme, with the remaining 36 weeks covering the maintenance period (web-based peer support and goal-tracking only).

The BetaMe programme underwent substantial pre-testing, and a pilot in 2015 demonstrated very positive results. In the pilot evaluation, 117 people with pre-diabetes participated from five general practices within one region of New Zealand (the Midlands Health Network). Baseline and follow-up measures at 16 weeks included HbA1c, weight, waist circumference, pre-diabetes status (defined as HbA1c 41--49 mmol/mol) and blood pressure. Of the 117 patients, 108 completed the programme (92%). Of these, 91% reduced their HbA1c, 94% lost weight (mean = 4.2 kg), 87% had reduced waist circumference (mean = 4.2 cm) and 78% had final HbA1c levels below the pre-diabetes range \[[@CR25]\].

The feedback from pilot participants was extremely positive. Participants strongly endorsed both the coaching and community aspects of the programme (77% found these the most helpful aspect). Most (84%) reported that they were likely to recommend BetaMe to someone else, while only 2% said they were unlikely to do so. In a recent US review of digital diabetes prevention and self-management solutions in the workplace, the BetaMe programme ranked top for patient engagement and was in the top five overall \[[@CR26]\].

In this study, we will undertake a randomised controlled trial to compare the BetaMe programme with usual primary care for patients with T2DM and pre-diabetes, examining the impact on HbA1c and weight as well as waist circumference, blood pressure and a number of self-reported measures of effectiveness at 12 months. This work will address several gaps in the current knowledge base around comprehensive self-management programmes for diabetes. First, most existing studies examine only one part of what is considered to be a self-management programme. For example, a 2011 meta-analysis of 22 trials with 1657 participants concluded that there was evidence that mobile-phone applications led to significant improvements in glycaemic control (a mean reduction in HbA1c of 6 mmol/mol over a mean 6 months' duration) \[[@CR16]\]. However, most of the programmes studied were not comprehensive in that their interventions focussed solely on monitoring reminders or entering glucose measurements; did not involve providers or current clinical practice; or did not personalise the programme to individuals. Second, the current study will address a lack of evidence on the effectiveness of self-management programmes for Māori and Pacific individuals. Third, unlike most other studies that focus on 'people with diabetes' or 'pre-diabetes' our randomised controlled trial (RCT) will include participants with both pre-diabetes and T2DM, and will measure the effectiveness of the intervention for both groups. This will be more representative of the effectiveness of this intervention in the real clinical setting, and will give a better idea of the relative benefits for those with pre-diabetes compared to those with T2DM.

Methods {#Sec2}
=======

Aims, design and setting {#Sec3}
------------------------

The primary aim of this study is to evaluate the effectiveness of the BetaMe programme versus usual care among primary care populations in improving the control of T2DM and pre-diabetes, as measured by change in HbA1c and weight over a 12-month period.

The secondary aims, which will be explored using secondary analysis of the data, are to evaluate the effectiveness of the BetaMe programme versus usual care in:Improving HbA1c and weight outcomes at 12 months for Māori and Pacific participants specifically (combined across T2DM and pre-diabetes groups);Improving short-term weight management among those with T2DM and pre-diabetes (at 4 months, both overall and reported for Māori and Pacific participants);Improving other health-related outcomes, including waist circumference, blood pressure, health-related quality of life and self-reported self-management (overall and reported for Māori and Pacific participants)

The study will be a two-arm, parallel-group, individually randomised controlled trial for people with pre-diabetes and T2DM, comparing the BetaMe programme with usual primary care (active control), with investigator-blinded assessment of outcomes (see Fig. [1](#Fig1){ref-type="fig"} for the flowchart of the BetaMe study, Additional file [1](#MOESM1){ref-type="media"} for the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Checklist and Fig. [2](#Fig2){ref-type="fig"} for the SPIRIT Figure).Fig. 1Flowchart of the BetaMe studyFig. 2Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure

The study will be based in two regions of NZ, Midlands and Greater Wellington, through two Primary Healthcare Organisations (PHOs, Midlands Health Network and Compass Health), and a large Māori healthcare provider (Whai Oranga o Te Iwi). These providers collectively include around 800,000 patients. The research team will work directly with the two PHOs to identify and recruit practices that are interested in the study and able to commit to the study timeframes and process requirements. Practice recruitment will be through an opt-in process.

Participants {#Sec4}
------------

Participants with pre-diabetes or T2DM will initially be identified using clinical data held by participating PHOs and practices. Those identified as having T2DM and meeting the eligibility criteria below will be included. Those with HbA1c in the 41--49-mmol/mol range in the 2 years prior to commencing the study, and with no recorded diagnosis of T2DM, will be classified in the pre-diabetes group.

Patients will be eligible for inclusion if they meet the following inclusion criteria:Have a current HbA1c of 41--70 mmol/mol (either from a test within 3 months prior to invitation to the study, or on the basis of an HbA1c test taken by the research team at invitation to the study)Are not currently on insulin treatment for diabetesAdults aged between 18 and 75 years, enrolled in participating practicesHave daily Internet access (on any of computer/tablet/smartphone)Are able to provide informed consent

Patients will not be eligible for the study if they:Are pregnantHave cognitive impairment likely to be sufficient to hinder their understanding of the study or the programme, as this may negatively affect their self-management behaviour \[[@CR27]\]Are unable to read and write in EnglishAre unable to use phone or computer due to physical disability such as poor eyesight or manual dexterity

Recruitment {#Sec5}
-----------

The PHOs or practices will generate a list of current people with T2DM and pre-diabetes, using an HbA1c result of 41--64 mmol/mol within the past 24 months. Individuals that are retested at baseline and return an HbA1c result of 65--70 mmol/mol remain eligible for the study. Patients who are known not to meet the other eligibility criteria will be removed from this list. The remaining patients will be invited by the practice for the research team to contact them.

A research nurse will then contact participants to explain the study, confirm eligibility and obtain informed consent. Baseline data will be collected at this point including HbA1c (for those who do not have an HbA1c test result in preceding 3 months), weight, height, waist circumference and blood pressure (using standardised approaches); along with a health-related quality of life measure, a validated measure of chronic condition self-management; and a validated measure of diabetes-specific behaviours (e.g. frequency of blood sugar monitoring). Details of the measures and questionnaires are in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}.Table 2Summary of outcome measuresOutcomesTime point^a^Measurement/definitionPrimary outcome measures Change in HbA1cAt 12 monthsMeasured using whole blood sample collected in EDTA tube (2 ml minimum) using Variant Turbo Ion Exchange HPLC. Participants will either have a blood sample taken by the research nurse, or will be provided with a laboratory request form for an HbA1c blood test that will be taken as per usual processes within a week of the assessment period. Change in weightAt 12 monthsMeasured in kilograms using calibrated digital scales and standardised methodsSecondary outcome measures Change in HbA1cAt 4 monthsMeasured using whole blood sample collected in EDTA tube (2 ml minimum) using Variant Turbo Ion Exchange HPLC (as above) Change in weightAt 4 monthsMeasured in kilograms using calibrated digital scales and standardised methods Change in waist circumferenceAt 4 and 12 monthsMeasured in millimetres using tape measure using standardised methods Change in blood pressureAt 4 and 12 monthsMeasured using a calibrated syphgmomanometer using a standard approach (blood pressure taken when participant has been sitting quietly for 5 min, without eating, drinking or smoking. They will be asked to have feet flat on the floor, with their back up against the back of the chair, and their left arm straight on the table). Three measures will be taken with the lowest of the last two measures recorded Change in self-managementAt 4 and 12 monthsMeasured using the Partners in Health Scale \[[@CR37]\] Change of score in diabetic-specific behaviours and outcomesAt 4 and 12 monthsMeasured using the Summary of Diabetes Self-Care Activities tool, which assess participants' self-care activities \[[@CR38]\] Health-related quality of lifeAt 4 and 12 monthsMeasured using the five-level EuroQol five dimensions questionnaire (EQ-5D-5 L) Change in score of diabetes-specific outcomesAt 4 and 12 monthsMeasured using the Diabetes Distress Scale \[[@CR39]\] Change in dose of insulinAt 4 months relative to baseline, and 12 months relative to 4 monthsCategorised as (1) starting insulin in current time period; (2) increasing dose of insulin in current period; (3) reducing dose of insulin in current period or (4) stopping insulin in current period. Data will be collected from patients, verified where possible from clinic records Change in dose of metforminAt 4 months relative to baseline, and 12 months relative to 4 monthsCategorised as (1) starting metformin in current time period; (2) increasing dose of metformin in current period; (3) reducing dose of metformin in current period or (4) stopping metformin in current period. Data will be collected from patients, verified where possible from clinic records Change in dose of other oral hypoglycaemic agents (not metformin)At 4 months relative to baseline, and 12 months relative to 4 monthsCategorised as (1) starting oral hypoglycaemic agents in current time period; (2) increasing dose of oral hypoglycaemic agents in current period; (3) reducing dose of oral hypoglycaemic agents in current period or (4) stopping oral hypoglycaemic agents in current period. Data will be collected from patients, verified where possible from clinic records*EDTA* ethylenediaminetetracetic acid, *HbA1c* glycosylated haemoglobin, *HPLC* high-performance liquid chromatography^a^All time periods are time after recruitment, and compared with baseline with exception of changes in medication dose specified aboveTable 3Summary of variables measured in the patient questionnaireMeasureDetailsSourceBaseline patient demographic questionsName, address, date of birth, ethnicityAll questions are based upon Statistics New Zealand census questions:\
available from: <http://archive.stats.govt.nz/methods/classifications-and-standards/classification-related-stats-standards/gender-identity.aspx?_ga=2.83660500.398110315.1519357080-701333020.1444617687>Smoking questionTo ascertain current, never and ex-smokersParts of the New Zealand Health Survey smoking panel\
Ministry of Health. 2015. Adult Questionnaire (Year 5) 1 July 2015 to 30 June 2016: New Zealand Health Survey. Wellington: Ministry of Health. Available from: <http://www.health.govt.nz/publication/questionnaires-and-content-guide-2014-15-new-zealand-health-survey>Healthcare utilisation questionsPrimary care, afterhours, Emergency Department ED and hospital admissionsModified from the New Zealand Health Survey\
Ministry of Health. 2015. Adult Questionnaire (Year 5) 1 July 2015--30 June 2016: New Zealand Health Survey. Wellington: Ministry of Health. Available from: <http://www.health.govt.nz/publication/questionnaires-and-content-guide-2014-15-new-zealand-health-survey>Comorbid conditions questionsList of conditionsList is a modified version of:\
Sanga O, Stucki G, Liang M, Fossel AH, Katz JN. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. *Arthritis Rheum* 2003; 49: 156--63. \[[@CR62]\]Medication questionsName, dose and frequencyQuestions developed by research team.Health-related quality of life (EQ-5D-5 L)Health profile and Visual Analogue Scale ratingPermission granted to use the paper and REDCap versions of the EQ-5D-5 L. Available from: <https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/>The summary of diabetes self-care activitiesOriginal scale included 5 domains on self-care with additional items on what care has been recommendedWe have focussed on the self-care domains only. We have kept the general categories outlined in the original scale, but have modified the questions on diet, blood sugar, foot checks, smoking and medications to be of use for our randomised controlled trial (RCT).\
Toobert DJ, Hampson SE, Glasgow RE. The summary of diabetes self-care activities measure: results from 7 studies and a revised scale. Diabetes care 23.7 (2000): 943--950. \[[@CR38]\]\
Permission to use this scale is from: <http://www.ori.org/sdsca/purchase>.Diabetes Distress Scale17 questions on the level of distress resulting from diabetesPermission granted to use the scale, and modify to also include pre-diabetics. Available from: <http://behavioraldiabetes.org/scales-and-measures/#1448434304099-9078f27c-4106>\
Fisher L, Glasgow RE, Mullan JT, Skaff MM, Polonsky WH. Development of a brief diabetes distress screening instrument. *Ann Fam Med* 2008;6(3):246--252. \[[@CR39]\]\
Polonsky WH, Fisher L, Esarles J, Dudl RJ, Lees J, Mullan JT, Jackson R. (2005). Assessing psychosocial distress in diabetes: Development of the Diabetes Distress Scale. Diabetes Care, 28, 626--631. \[[@CR63]\]\
Fisher L, Hessler DM, Polonsky WH, Mullan J. (2012). When is diabetes distress clinically meaningful? Establishing cut-points for the Diabetes Distress Scale. Diabetes Care, 35, 259--264. \[[@CR64]\]Partners in Health Scale12 questions on chronic disease self-managementPermission to use the scale, April 2017.\
Smith D, et al. Measuring chronic condition self-management in an Australian community: factor structure of the revised Partners in Health (PIH) scale. Quality of Life Research (2016), 1--11. \[[@CR37]\]\
Petkov J, Harvey P, Battersby MW. The internal consistency and construct validity of the Partners in Health Scale: validation of a patient rated chronic condition self-management measure. Quality of Life Research 19.7 (2010), 1079--1085. \[[@CR65]\]

Intervention arm {#Sec6}
----------------

BetaMe is Internet-based and delivered using both mobile and web-based platforms by Melon Health Ltd. \[[@CR22]\]. The BetaMe intervention aims to strike a balance between 'tailoring' to individuals and delivering an intervention that is applied consistently enough to allow its impacts to be measured.

The BetaMe intervention consists of four separate components; health coaches, provision of evidence-based educational resources, goal tracking and peer support:Health coaching. The health coaches are all either qualified personal trainers or registered nurses trained in motivational interviewing, cognitive behavioural therapy, and nutrition, and have completed the Heart Foundation Pacific Heartbeat Community Nutrition course. Health coaches arrange an initial one-on-one session with participants. The purpose of this first 1 h session is for health coaches to work with participants to develop goals tailored to their needs and values. The session follows a set format. Māori and Pacific coaches are available. Once these goals have been set and agreed on, participants' goals are entered into their profile on the BetaMe system. Coaches will continue to work with participants, and will message participants weekly to check on their progress, reinforce information from the modules and arrange further meetings at frequencies that suit the participant (these can be weekly, fortnightly or less frequently if preferred). These subsequent meetings are generally around 15--20 min in length. All meetings with the coaches will be by audio or video, as per the participant's preference. Support and clinical governance of the health coaches is provided by a clinical psychologist, general practitioner and an experienced health coach. Coaches also regularly interact with one another via an online forum (separate from patient forums) to share any problems they are having and solutionsHealth literacy component. There are eight key education modules introduced to participants via the web and mobile platform with attached resources (videos, infographics, articles, tips, tools, meal ideas and mini-quiz). The key messages in the modules are reinforced in corresponding email newsletters, discussions on the newsfeed initiated by the community manager and by the participant's coach. Every 2 weeks, a new module is released that presents participants with a range of topics that offer key messages to help them to learn about and manage their own health. The modules cover risk factors for T2DM and pre-diabetes, healthy eating and physical activity, identifying triggers for less healthy decisions and establishing healthy habits, sleep and shift work, meal planning, problem solving, healthy coping and mindfulness (see Additional file [2](#MOESM2){ref-type="media"} for more information)Goal tracking. Participants are encouraged to track their progress towards their goals (including healthy eating, physical activity, weight, happiness and sleep). They will be provided with a set of digital scales and a tape measure so they can take their own measurements and track their progress. They will be able to share these data with their health coach at any time, or with their physician by email or at their next appointmentPeer support. The programme also includes peer support with real-time chat within a private and secure online social network monitored by a community manager who is a registered nurse trained in nutrition. This person monitors the community to ensure nothing unsafe (like personal details, or negative health messages) is shared, and that people are supported and supportive. They will also reinforce key messages, highlight local events in the area, start conversations and welcome new people to the community. The community manager also provides a point of contact for both technical support, and for support more generally, particularly after the first 16 weeks of the programme when the health coaching module is completed.

In the first 16 weeks of the programme, participants will set goals, work with health coaches, receive the evidence-based modules and be encouraged to use goal tracking and participate in the peer support programme. After that time, participants will be encouraged to continue tracking and participating in peer support, for the remainder of the 52-week programme. Information from the modules is available for the entire 52-week period.

At the time of randomisation, contact details for participants randomised to the intervention arm will be forwarded to Melon Health Ltd. (with participant permission). A health coach will then contact the participant within five working days to initiate the programme. Those randomised to the intervention arm will begin the BetaMe programme whilst continuing to receive usual clinical care from their primary healthcare team. They will also receive resources produced and provided by Diabetes NZ.

### Technical aspects of the mHealth platform {#Sec7}

Melon Health's platform is built to maximise patient confidentiality and general security of the application at all levels. The system exceeds New Zealand privacy requirements and meets US HIPAA (Health Insurance Portability and Accountability Act) security rules for health data, with regular auditing by external security specialists.

The platform currently integrates with over 350 wearables and biometric sensors through its open API (application programming interface), and platform is accessible through a web-based application or Android/iOS applications.

Control arm {#Sec8}
-----------

Participants in the control arm will receive usual care. Although this may vary somewhat between practices and GPs, the key interest is the extent to which the BetaMe programme may improve outcomes beyond that expected in the context of usual care. For people with T2DM, this would typically involve an annual diabetes review to monitor glycaemic control and assess the patient for the presence of any diabetes complications and a review of treatment. In addition, it could include education and advice on lifestyle factors, such as diet and exercise, provided by a trained practice nurse or diabetes specialist nurse. For people with pre-diabetes, usual care would typically include lifestyle advice and education about diet and exercise, and an annual HbA1c.

The study team will also provide participants in the control arm with standard information about pre-diabetes and T2DM and its management, from resources produced and provided by Diabetes NZ (Pamphlets entitled 'Pre-diabetes', 'Diabetes and Healthy Food Choices', and 'Live Well with Diabetes', available at <https://www.diabetes.org.nz/pamphlet-ordering/>). This is to increase retention of control arm participants in the study, and to ensure that all patients have basic information on T2DM and pre-diabetes.

Randomisation and blinding {#Sec9}
--------------------------

Based upon their baseline HbA1c test results (pre-diabetes or diabetes range), participants will be randomised into the intervention or control arm (1:1 allocation) using a computer-generated randomisation schedule stratified by participating practice and ethnicity (and separate for the two HbA1c-level groups). Randomisation will be completed within two working days of the completed baseline assessment. To ensure allocation concealment, randomisation will be centrally determined from within the REDCap electronic data capture platform *after* the patient is enrolled in the study (following the first assessment with the research nurse and when full eligibility based on current HbA1c level has been determined). To ensure balance in numbers allocated to each study arm, randomisation lists will be blocked.

The randomisation allocation list will not be visible to the team member(s) requesting the allocation, and this team member(s) will only have details on the patient ID, practice, and ethnicity when requesting allocation for any patient. The exact length of each randomisation block will be kept in a separate document held by the principal investigator (PI), project manager and project statistician, and thus will not be available to the team member(s) responsible for determining allocation.

Given the nature of the intervention, it is not possible to keep participants blind to their intervention status. Research nurses taking objective measurements will be kept blind to the intervention status of participants to the extent possible. However, when the nurse meets with the participant at the 4- and 12-month follow-up visits, it is not possible to guarantee that the nurses remain blind to the intervention allocation of the participant. The results dataset will be stored with the study arm identity blinded by code. The key to this code will be held independent of the analysis dataset by the PI, a second member of the research team (MM), and an independent member of the internal Data Monitoring Group. Data cleaning and analysis will be conducted by a statistician who is blind to group allocation. Once analysis is complete, the results will be unblinded.

Outcome measures {#Sec10}
----------------

The co-primary outcomes are changes in HbA1c and weight at 12 months. HbA1c provides the most sensitive measure of glycaemic control among those with T2DM. High levels are predictive of higher levels of complications and mortality. Weight (and waist circumference) are associated with T2DM, cardiovascular disease, several cancers and overall mortality \[[@CR28]--[@CR30]\]. We will focus on weight in kilograms as this is the most common outcome in systematic \[[@CR31], [@CR32]\] and Cochrane reviews, \[[@CR33], [@CR34]\] but for completeness we will also report differences in units of Body Mass Index (BMI).

Secondary outcomes are:Change in waist circumference at 12 monthsChange in blood pressure at 12 months. High blood pressure (common amongst people with diabetes) is associated with a higher risk of cardiovascular disease and mortality, and is amenable to lifestyle interventions \[[@CR35], [@CR36]\]

Additional self-reported outcomes include:Medications (regular prescription medications), and changes to medications and dosesChanges in self-management of chronic conditions using the Partners in Health Scale. This is a validated tool for self-reported self-management of chronic conditions \[[@CR37]\]Diabetes-specific behaviours and outcomes will be measured using two validated instruments: the Summary of Diabetes Self-Care Activities tool, which assesses participants' self-care activities \[[@CR38]\]; and the Diabetes Distress Scale which differentiates those with high and low levels of distress \[[@CR39]\]Health-related quality of life measured using the five-level EuroQol five dimensions questionnaire (EQ-5D-5 L) \[[@CR40]\]. Short-term outcomes: we will assess primary and secondary outcomes at 4 months. This will give an indication of the effect of the 'active' part of the intervention. Research has shown that even short-term decreases in HbA1c can have a long-term effect on health outcomes, with effects tending to attenuate over time \[[@CR12], [@CR13], [@CR41]\]

Outcomes will be assessed for all participants (regardless of whether they complete the intervention) by trained nurses at baseline, 4 months and 12 months (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}).

Sample size and analysis {#Sec11}
------------------------

All primary analyses will be based on intention-to-treat principles (with individuals analysed in the group to which they were randomised). Demographic and baseline characteristics will be summarised using descriptive statistics. Both HbA1c and weight will be analysed as continuous variables. For the HbA1c primary outcome, analysis will be conducted both combined and separately for pre-diabetes and T2DM. For weight, the primary analysis will combine participants with pre-diabetes and T2DM. Analysis will use linear mixed models, comparing mean outcome levels between intervention and control arms at the 12-month endpoint, adjusted for initial HbA1c level (accounting for baseline differences in outcome) and for other important baseline covariates (age, gender, ethnicity, weight). This analysis will include the 4-month measurements, providing some information for those individuals subsequently lost to follow-up and hence missing final outcome data (mixed models analysis treats these final data as missing at random conditional on baseline and intermediate covariates, i.e. these individuals are expected on average to have final outcomes similar to other people with the same baseline covariates and HbA1c trajectories). As the study involves repeated measures data, these models will include random effects for individuals to account for correlation between measurements from the same person at different follow-up times.

The study is powered in the pre-diabetes group to detect a difference of 2.5 mmol/mol between study arms (80% power, alpha = 0.05, presuming SD = 5.5 mmol/mol \[[@CR42]\]). This requires a sample size of 76 per study arm (152 total). In the pilot study, the mean reduction in HbA1c was 2.6 mmol/mol. The sample size for the T2DM group is powered to detect a minimal clinically important difference \[[@CR43], [@CR44]\] of 5.5 mmol/mol between study arms (80% power, alpha for comparison = 0.05, presuming a standard deviation of 15 mmol/mol in this group \[[@CR16]\]). This requires a sample size of 117 per study arm (234 total). This gives a combined sample size of 386 people with pre-diabetes and people with T2DM. To account for loss of precision due to patients lost to follow-up (projected at 10% \[[@CR45], [@CR46]\]), we will recruit 430 patients at baseline (note that all participants will be included in linear mixed models analysis, even if missing final endpoint data, which reduces bias in estimating effect size, but there is still loss in statistical power compared to having complete follow-up data).

Analysis of weight differences between study arms will use the same analytical methods as for the HbA1c outcome. For these weight analyses, those with pre-diabetes and T2DM will be pooled prior to analysis as the relevant intervention target weight loss is the same for these two groups. Analysis will be stratified on patient group to account for the pooled approach, and we will also report weight differences by study arm within each patient group. The comparison of weight loss in the combined patient group is powered to detect a difference between study arms of 5 kg (80% power, alpha = 0.05, SD = 15 kg in this group \[[@CR47]\]). This requires a sample size of 142 per study arm (284 total), which is within the combined sample size calculated for the HbA1c outcome.

We will also estimate differences in HbA1c and weight endpoints by study arm for each of the stratified randomisation ethnic groups (Māori, Pacific, other ethnicities), and will report the mean intervention effect and 95% confidence interval for each group. Proportions of patients meeting HbA1c and weight-loss targets will also be analysed by ethnic group with logistic regression (adjusted for baseline covariates), and adjusted absolute risk differences in treatment outcomes will be computed to quantify treatment effectiveness \[[@CR48]\]. Assuming that 20% of the sample will be Māori (*n* = 234 × 0.2 = 46 Māori participants) gives an anticipated margin of error on the intervention effect of ± 4.5 mmol/mol for HbA1c in the diabetic group.

Analysis of self-reported outcomes will be conducted in a similar way.

Results will be actively disseminated (see Additional file [3](#MOESM3){ref-type="media"}).

### Data management {#Sec12}

Baseline and follow-up data are entered directly by patients and research nurses at the time of the relevant assessments in to a REDCap database. Range checks are in place for relevant variables such as HbA1c levels (41--70 mmol/mol). All data are checked by research nurses at the time of their entry and those variables that are used for stratified randomisation (ethnicity, practice and HbA1c) are re-checked by the research manager prior to randomisation. Participants' data will be de-identified by a unique code number and information linking that code to a particular patient (NHI and unique trial-specific code number) will be kept in a secure location with password protection. A master list which links the patients' NHI and trial code number will be kept so any information about the study, including results, can be communicated to participants. Analysis will be carried out on de-identified data. All trial-specific data for the study will be securely stored by the research team for 10 years once the trial has ended.

### Data monitoring {#Sec13}

An independent Data Monitoring Group is not required for this study because the study is low risk in terms of likelihood of life-threatening complications or serious adverse events, the study team has no professional or financial links with the company that is delivering the intervention, and it will not be necessary to instigate stopping rules because there will be no interim analyses of efficacy \[[@CR49]\]. An internal Data Monitoring Group will be convened at 2-monthly intervals which will consist of the study PIs (DS and MM) and the biostatistician (JS). This group will also include an independent senior researcher. This group will assess the effectiveness of study procedures, review any potential adverse events and review and approve any amendments to study protocols. Other members of the research group will provide advice and input if requested.

Process evaluation {#Sec14}
------------------

At the end of the study, there will be a process evaluation, which will include assessments of implementation of the BetaMe programme and mechanisms of action. Data will be collected from three sources: (1) from the mobile/web platform to identify key usage patterns; (2) with consent from the participants, health coaches will record audio interactions with participants and will log key reasons for contact (a random subset of the coaching sessions will be assessed by the research team for consistency with the log); and (3) participants will be invited to provide individual feedback on the acceptability and usefulness of the intervention at the end of the study period.

Focus groups, lasting approximately 1 h each, will be held in each region to obtain in-depth feedback about the intervention and how participants interacted with it. Usage will be described, and linked to outcomes using standard quantitative analytic approaches (for example, proportions accessing health coaches will be reported, with 95% confidence intervals; frequency of accessing health coaches or engaging online will be reported as median access with range/interquartile range). Focus group data will be coded thematically, with key issues identified.

Trial registration {#Sec15}
------------------

The trial is registered with the Australian New Zealand Clinical Trials Registry on 19 April 2017. Registration number: ACTRN: ACTRN12617000549325. See [http://www.ANZCTR.org.au/ACTRN12617000549325.aspx](http://www.anzctr.org.au/ACTRN12617000549325.aspx). The full protocol is available at this site, including consent forms and detailed documentation. Any important protocol modifications will be reported to this organisation.

This trial's Universal Trial Number (UTN) is U1111--1189-9094.

Discussion {#Sec16}
==========

Long-term conditions pose a great burden to patients, family/whānau and health services. Self-management interventions are a potential way to address this burden with evidence that they can be effective in improving physical and mental health. Important gaps in evidence remain, and are a barrier to implementation. The BetaMe programme is an integrated, evidence-based, comprehensive, self-management programme delivered by mobile and web-based technology. A pilot of 117 patients with pre-diabetes was extremely successful with 78% of people reducing their HbA1c level below pre-diabetes range over 4 months. However, the study was volunteer-based and did not incorporate a comparison arm.

This paper describes the protocol of a study that will address the question of whether this kind of programme is likely to be effective in reducing HbA1c and weight among people with T2DM and pre-diabetes in a primary care environment. It addresses shortcomings of previous studies and includes an explicit aim to assess the effectiveness of this kind of programme among Māori and Pacific people who have higher rates of T2DM and pre-diabetes than other ethnic groups in NZ.

If found to be effective, this programme would allow healthcare providers to deliver an intervention that is person-centred and supports the self-care of people with T2DM, pre-diabetes and potentially other LTCs.

Trial status {#Sec17}
============

This paper is based on protocol version 1.2, dated 1 August 2017. Recruitment to the study began on 9 June 2017. Approximate date of recruitment completion: February 2018.

Additional files
================

 {#Sec18}

Additional file 1:SPIRIT Checklist. (DOC 120 kb) Additional file 2:Health literacy modules. (DOCX 14 kb) Additional file 3:Dissemination policy. (DOCX 18 kb)

BMI

:   Body Mass Index

EQ-5D-5L

:   five-level EuroQol five dimensions questionnaire

LTC

:   Long-term conditions

NHI

:   National Health Index

NZ

:   New Zealand

PHO

:   Primary Healthcare Organisation

PI

:   Primary investigator

T2DM

:   Type 2 diabetes mellitus
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